Acceptance for FOSRENOL , which controls phosphate levels in renal dialysis patients Sweden approves innovative treatment to reduce phosphate risk in sufferers with end stage renal failure; today FOSRENOL to enter EU mutual recognition procedure Sweden’s MPA provides today granted the first regulatory approval in the globe for FOSRENOL , a non-calcium, non-aluminium phosphate binding medicine developed to regulate phosphate amounts in renal dialysis sufferers. Sweden will now end up being the Reference Member State in the EU Mutual Acknowledgement Procedure for FOSRENOL, and this may be the first step in securing marketing acceptance throughout Europe ed aide more info .

Other Articles From "gastroenterology":

Random Articles